Biosimilar Safety and Efficacy Comparable to Biologic Treatment in IBD Patients

Biologic compounds have long been considered the gold standard immunosuppressive therapy for moderate-to-severe IBD, but growing evidence suggests that biosimilars offer similar benefits at a much lower cost. Now, a new Cleveland Clinic study comparing the biologic compound infliximab with the biosimilar infliximab-abda shows that the two therapies are comparable in both safety and efficacy

Impact of Biologics Use on Bone Loss in Patients with IBD

IBD patients treated with biologics are significantly less likely to have osteoporosis and bone fractures compared with those who did not, according to the largest individual study to date investigating the prevalence of osteoporosis and bone fractures in IBD patients with and without biologics therapy.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Advertising Policy